...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BETonMACE details
13
May 16, 2018 06:09PM
3
May 16, 2018 07:08PM
7
May 16, 2018 07:38PM
6
May 16, 2018 08:11PM

May 16, 2018 08:15PM
6
May 16, 2018 08:32PM

Devil's advocate here Bear....

What's in the blank "redacted" information section 4.22?  This is what the company's Sedar filing says is included:

Schedule 4.22 hereto sets forth as of the Closing Date, a true and accurate summary of the clinical trial protocol and achievements to-date including (i) target sample size, (ii) current enrolment size, (iii) primary and secondary endpoints, (iv) list of participating sites; (v) average patient profile; (vi) description of drug, dosing, and route of administration; (vii) target duration of study and current status, (viii) target participation duration of patients; (ix) target events and events to-date; (x) target relative risk reduction and relative risk reduction to-date; (xi) events until interim analysis; (xii) assumed dropout rate and rate-to-date 

They say its included....do you think they're lying?

7
May 16, 2018 09:07PM
4
May 16, 2018 10:12PM
5
May 16, 2018 10:18PM
3
May 16, 2018 10:27PM
4
May 16, 2018 11:08PM
5
May 17, 2018 12:16AM
3
May 17, 2018 06:33AM
2
May 17, 2018 07:13AM
1
May 17, 2018 08:24AM
Share
New Message
Please login to post a reply